Sterilization Validation Documents

1. Key takeaways

Myanmar’s requirements for sterilization documentation are layered in two tiers by class: (1) all sterile products must state the sterilization method; and (2) Class C and Class D products must additionally submit sterilization validation data. For Class A and Class B the requirement is “if applicable”.

GRZAN note: the first step of the judgment is to confirm whether the product is supplied in a sterile state. If it is supplied sterile, the sterilization method description is mandatory; if it additionally belongs to Class C or Class D, the sterilization validation data is also mandatory. These two judgments are independent of each other and must be completed separately — the class answers the second question only after the supply status has answered the first.

• All sterile products — sterilization method description is mandatory;
• Class A — if applicable;
• Class B — if applicable;
• Class C — required, including sterilization validation data;
• Class D — required, including sterilization validation data.

For non-sterile Class A and Class B products, neither document is triggered: the supply-status judgment fails the first test, so the “if applicable” clause simply never becomes active. The value of separating the two judgments is that a team can walk through them in order and arrive at one of three clear outcomes — nothing needed, method description only, or method description plus validation data — instead of arguing about class labels in the abstract.

2. Legal basis

The document requirement, its class-specific depth and the related dossier files are summarised below. The class logic follows the same four-class framework used across the technical documentation: the higher the class, the more the sterilization file must contain. The related documents listed — the manufacturing flow chart, the stability and shelf-life data and the certificate of analysis — are the files the sterilization content must stay consistent with when the dossier is reviewed as a whole.

3. Expert insights

Insight 1: “if applicable” means applicable when the product is supplied in a sterile state. This wording anchors the judgment criterion in the supply status rather than the product form. Companies must check their own product’s supply specification: the same device family can exist in sterile and non-sterile variants, and the obligation follows the variant actually being registered, not the family name.

Insight 2: sterilization validation for Class C and Class D products is unconditionally required. This means that even where the product’s supply specification is unusual, once the product belongs to Class C or Class D the sterilization validation data must be submitted. There is no relief available from packaging or marketing arrangements; the class alone drives the obligation. Teams registering a high-class product line should therefore treat the validation study as a fixed cost of the class, budgeted and scheduled without waiting for the supply-status discussion to conclude.

Insight 3: the sterilization method description and the sterilization validation data are two different levels. The former describes which sterilization method is used; the latter proves that the method is effective. The two cannot substitute for each other: a description without validation tells the reviewer what is done but not whether it works, while validation without a clear method description leaves the reviewer unable to connect the data to a process.

Insight 4: sterilization validation and stability data are interrelated. The expiry validation of the sterile barrier system typically supports two conclusions at once — the continued effectiveness of sterilization and the shelf life of the product. Sharing the study design and the data between the two workstreams therefore saves effort and, just as importantly, guarantees the two conclusions cannot contradict each other, which matters because the certificate of analysis and the labelling both inherit the dated conclusions these studies produce.

Insight 5: the sterilization file sits alongside the electrical safety file as part of the additional requirements. Companies should build a complete additional-document list that crosses the two dimensions — active and sterile — so that a device which is both active and sterile triggers both additional obligations and neither is forgotten. A two-by-two check at project kickoff, repeated whenever a variant is added, keeps the list current for the whole product range.

4. Practical recommendations

• Confirm whether the product is supplied in a sterile state. The necessity of the method description follows from this.
• Prepare sterilization validation data unconditionally for Class C and Class D products. Supply specifications do not change this.
• Prepare the method description and the validation data separately. One does not replace the other.
• Coordinate sterilization validation with the stability studies. Share data and study designs.
• Build the complete additional-document list. Cross-check along the active and sterile dimensions.

The sequencing that works in practice is straightforward: settle the supply-status question at product definition, fix the class from the classification rules, and only then commission the validation work, scaled to whichever tier the two answers select. Because validation studies are slow and sample-dependent, deciding them early protects the submission calendar even when the resulting file is, by class A or B standards, only a short method description.

5. Verification checklist

• □ Determined whether the product is supplied in a sterile state
• □ Sterilization method description prepared for sterile products
• □ Sterilization validation data prepared for Class C and Class D products
• □ Sterilization method description distinguished from sterilization validation data
• □ Sterilization validation coordinated with the stability studies
• □ Cross-checking list along the active and sterile dimensions established
• □ Sterilization file included in the registration register management

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com